ThuliumV1, Pascal, Curation, bibRecord, 000192

Thulium:YAG Vapoenucleation in Large Volume Prostates

Identifieur interne : 000192 ( Pascal/Curation ); précédent : 000191; suivant : 000193

Thulium:YAG Vapoenucleation in Large Volume Prostates

Auteurs : Thorsten Bach [Allemagne] ; Christopher Netsch [Allemagne] ; Laura Pohlmann [Allemagne] ; Thomas R. W. Herrmann [Allemagne] ; Andreas J. Gross [Allemagne]

Source :

The Journal of urology [ 0022-5347 ] ; 2011.

RBID : Pascal:12-0005789

Descripteurs français

Pascal (Inist)
- Adénome de la prostate, Thulium, Volume, Prostate, Laser, Traitement, Volatilisation, Néphrologie, Urologie.

English descriptors

KwdEn :
- Benign prostatic hyperplasia, Laser, Nephrology, Prostate, Thulium, Treatment, Urology, Volatilization, Volume.

Abstract

Purpose: Tm:YAG vapoenucleation was introduced as a minimally invasive treatment in patients with benign prostatic obstruction. The efficiency and safety of Tm:YAG vapoenucleation must still be confirmed in large volume prostates to prove the size independence of this promising treatment option. We evaluated the safety and efficiency of Tm:YAG vapoenucleation in patients with a prostate volume of 80 cc or greater and benign prostatic obstruction during a 12-month followup. Materials and Methods: Included in this trial were 90 consecutive patients undergoing 90 W Tm:YAG vapoenucleation. Vapoenucleation was done using the 2 μm continuous wave Tm:YAG laser combined with a mechanical tissue morcellator. We analyzed patient demographic, perioperative and 12-month followup data. Complications were assessed. Results: Mean preoperative prostate volume was 108.6 cc (range 80 to 200), mean International Prostate Symptom Score was 23.5 (range 8 to 35) and mean quality of life score was 4.3 (range 1 to 6). There was an 86% reduction (range 67% to 99%) in prostate volume on transrectal ultrasound by 12 months and an 88% decrease (range 58% to 100%) in prostate specific antigen. International Index of Erectile Function score remained stable. Peak urinary flow rate, International Prostate Symptom Score and quality of life improved significantly (p <0.001), as did post-void residual urine. The overall complication rate was manageable. Two patients required blood transfusion and 10 experienced early postoperative stress incontinence. During followup 7% of patients had symptomatic urinary tract infection and 2 had persistent grade I stress urinary incontinence. The reoperation rate due to urethral stricture was 1.8% during the 12-month followup. Conclusions: Tm:YAG vapoenucleation is a safe, effective and size independent treatment option for benign prostatic obstruction. As shown by reductions in transrectal ultrasound prostate volume and prostate specific antigen, complete removal of the adenoma can be achieved by this procedure.

A01	`01`	`1`		`@0 0022-5347`
A02	`01`			`@0 JOURAA`
A03		`1`		`@0 J. urol.`
A05				`@2 186`
A06				`@2 6`
A08	`01`	`1`	`ENG`	`@1 Thulium:YAG Vapoenucleation in Large Volume Prostates`
A11	`01`	`1`		`@1 BACH (Thorsten)`
A11	`02`	`1`		`@1 NETSCH (Christopher)`
A11	`03`	`1`		`@1 POHLMANN (Laura)`
A11	`04`	`1`		`@1 HERRMANN (Thomas R. W.)`
A11	`05`	`1`		`@1 GROSS (Andreas J.)`
A14	`01`			`@1 Departments of Urology, Asklepios Hospital Barmbek @2 Hamburg @3 DEU @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 5 aut.`
A14	`02`			`@1 MHH Medical School of Hannover @2 Hannover @3 DEU @Z 4 aut.`
A20				`@1 2323-2327`
A21				`@1 2011`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 2081 @5 354000505638820290`
A44				`@0 0000 @1 © 2012 INIST-CNRS. All rights reserved.`
A45				`@0 28 ref.`
A47	`01`	`1`		`@0 12-0005789`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 The Journal of urology`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Purpose: Tm:YAG vapoenucleation was introduced as a minimally invasive treatment in patients with benign prostatic obstruction. The efficiency and safety of Tm:YAG vapoenucleation must still be confirmed in large volume prostates to prove the size independence of this promising treatment option. We evaluated the safety and efficiency of Tm:YAG vapoenucleation in patients with a prostate volume of 80 cc or greater and benign prostatic obstruction during a 12-month followup. Materials and Methods: Included in this trial were 90 consecutive patients undergoing 90 W Tm:YAG vapoenucleation. Vapoenucleation was done using the 2 μm continuous wave Tm:YAG laser combined with a mechanical tissue morcellator. We analyzed patient demographic, perioperative and 12-month followup data. Complications were assessed. Results: Mean preoperative prostate volume was 108.6 cc (range 80 to 200), mean International Prostate Symptom Score was 23.5 (range 8 to 35) and mean quality of life score was 4.3 (range 1 to 6). There was an 86% reduction (range 67% to 99%) in prostate volume on transrectal ultrasound by 12 months and an 88% decrease (range 58% to 100%) in prostate specific antigen. International Index of Erectile Function score remained stable. Peak urinary flow rate, International Prostate Symptom Score and quality of life improved significantly (p <0.001), as did post-void residual urine. The overall complication rate was manageable. Two patients required blood transfusion and 10 experienced early postoperative stress incontinence. During followup 7% of patients had symptomatic urinary tract infection and 2 had persistent grade I stress urinary incontinence. The reoperation rate due to urethral stricture was 1.8% during the 12-month followup. Conclusions: Tm:YAG vapoenucleation is a safe, effective and size independent treatment option for benign prostatic obstruction. As shown by reductions in transrectal ultrasound prostate volume and prostate specific antigen, complete removal of the adenoma can be achieved by this procedure.
C02	`01`	`X`		`@0 002B14D02`
C02	`02`	`X`		`@0 002B20B02`
C03	`01`	`X`	`FRE`	`@0 Adénome de la prostate @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Benign prostatic hyperplasia @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Hiperplasia prostática benigna @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Thulium @2 NC @5 02`
C03	`02`	`X`	`ENG`	`@0 Thulium @2 NC @5 02`
C03	`02`	`X`	`SPA`	`@0 Tulio @2 NC @5 02`
C03	`03`	`X`	`FRE`	`@0 Volume @5 03`
C03	`03`	`X`	`ENG`	`@0 Volume @5 03`
C03	`03`	`X`	`SPA`	`@0 Volumen @5 03`
C03	`04`	`X`	`FRE`	`@0 Prostate @5 05`
C03	`04`	`X`	`ENG`	`@0 Prostate @5 05`
C03	`04`	`X`	`SPA`	`@0 Prostata @5 05`
C03	`05`	`X`	`FRE`	`@0 Laser @5 06`
C03	`05`	`X`	`ENG`	`@0 Laser @5 06`
C03	`05`	`X`	`SPA`	`@0 Láser @5 06`
C03	`06`	`X`	`FRE`	`@0 Traitement @5 08`
C03	`06`	`X`	`ENG`	`@0 Treatment @5 08`
C03	`06`	`X`	`SPA`	`@0 Tratamiento @5 08`
C03	`07`	`X`	`FRE`	`@0 Volatilisation @5 09`
C03	`07`	`X`	`ENG`	`@0 Volatilization @5 09`
C03	`07`	`X`	`SPA`	`@0 Volatilización @5 09`
C03	`08`	`X`	`FRE`	`@0 Néphrologie @5 11`
C03	`08`	`X`	`ENG`	`@0 Nephrology @5 11`
C03	`08`	`X`	`SPA`	`@0 Nefrología @5 11`
C03	`09`	`X`	`FRE`	`@0 Urologie @5 12`
C03	`09`	`X`	`ENG`	`@0 Urology @5 12`
C03	`09`	`X`	`SPA`	`@0 Urología @5 12`
C07	`01`	`X`	`FRE`	`@0 Appareil urogénital @5 37`
C07	`01`	`X`	`ENG`	`@0 Urogenital system @5 37`
C07	`01`	`X`	`SPA`	`@0 Aparato urogenital @5 37`
C07	`02`	`X`	`FRE`	`@0 Pathologie de l'appareil génital mâle @5 38`
C07	`02`	`X`	`ENG`	`@0 Male genital diseases @5 38`
C07	`02`	`X`	`SPA`	`@0 Aparato genital macho patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Pathologie de l'appareil urinaire @5 39`
C07	`03`	`X`	`ENG`	`@0 Urinary system disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Aparato urinario patología @5 39`
C07	`04`	`X`	`FRE`	`@0 Tumeur bénigne @5 40`
C07	`04`	`X`	`ENG`	`@0 Benign neoplasm @5 40`
C07	`04`	`X`	`SPA`	`@0 Tumor benigno @5 40`
C07	`05`	`X`	`FRE`	`@0 Pathologie de la prostate @5 41`
C07	`05`	`X`	`ENG`	`@0 Prostate disease @5 41`
C07	`05`	`X`	`SPA`	`@0 Prostata patología @5 41`
N21				`@1 002`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream Pascal, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000192

Links to Exploration step

Pascal:12-0005789

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Thulium:YAG Vapoenucleation in Large Volume Prostates</title>
<author><name sortKey="Bach, Thorsten" sort="Bach, Thorsten" uniqKey="Bach T" first="Thorsten" last="Bach">Thorsten Bach</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Departments of Urology, Asklepios Hospital Barmbek</s1>
<s2>Hamburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Netsch, Christopher" sort="Netsch, Christopher" uniqKey="Netsch C" first="Christopher" last="Netsch">Christopher Netsch</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Departments of Urology, Asklepios Hospital Barmbek</s1>
<s2>Hamburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Pohlmann, Laura" sort="Pohlmann, Laura" uniqKey="Pohlmann L" first="Laura" last="Pohlmann">Laura Pohlmann</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Departments of Urology, Asklepios Hospital Barmbek</s1>
<s2>Hamburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Herrmann, Thomas R W" sort="Herrmann, Thomas R W" uniqKey="Herrmann T" first="Thomas R. W." last="Herrmann">Thomas R. W. Herrmann</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>MHH Medical School of Hannover</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Gross, Andreas J" sort="Gross, Andreas J" uniqKey="Gross A" first="Andreas J." last="Gross">Andreas J. Gross</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Departments of Urology, Asklepios Hospital Barmbek</s1>
<s2>Hamburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">12-0005789</idno>
<date when="2011">2011</date>
<idno type="stanalyst">PASCAL 12-0005789 INIST</idno>
<idno type="RBID">Pascal:12-0005789</idno>
<idno type="wicri:Area/Pascal/Corpus">000192</idno>
<idno type="wicri:Area/Pascal/Curation">000192</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Thulium:YAG Vapoenucleation in Large Volume Prostates</title>
<author><name sortKey="Bach, Thorsten" sort="Bach, Thorsten" uniqKey="Bach T" first="Thorsten" last="Bach">Thorsten Bach</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Departments of Urology, Asklepios Hospital Barmbek</s1>
<s2>Hamburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Netsch, Christopher" sort="Netsch, Christopher" uniqKey="Netsch C" first="Christopher" last="Netsch">Christopher Netsch</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Departments of Urology, Asklepios Hospital Barmbek</s1>
<s2>Hamburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Pohlmann, Laura" sort="Pohlmann, Laura" uniqKey="Pohlmann L" first="Laura" last="Pohlmann">Laura Pohlmann</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Departments of Urology, Asklepios Hospital Barmbek</s1>
<s2>Hamburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Herrmann, Thomas R W" sort="Herrmann, Thomas R W" uniqKey="Herrmann T" first="Thomas R. W." last="Herrmann">Thomas R. W. Herrmann</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>MHH Medical School of Hannover</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Gross, Andreas J" sort="Gross, Andreas J" uniqKey="Gross A" first="Andreas J." last="Gross">Andreas J. Gross</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Departments of Urology, Asklepios Hospital Barmbek</s1>
<s2>Hamburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">The Journal of urology</title>
<title level="j" type="abbreviated">J. urol.</title>
<idno type="ISSN">0022-5347</idno>
<imprint><date when="2011">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">The Journal of urology</title>
<title level="j" type="abbreviated">J. urol.</title>
<idno type="ISSN">0022-5347</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Benign prostatic hyperplasia</term>
<term>Laser</term>
<term>Nephrology</term>
<term>Prostate</term>
<term>Thulium</term>
<term>Treatment</term>
<term>Urology</term>
<term>Volatilization</term>
<term>Volume</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Adénome de la prostate</term>
<term>Thulium</term>
<term>Volume</term>
<term>Prostate</term>
<term>Laser</term>
<term>Traitement</term>
<term>Volatilisation</term>
<term>Néphrologie</term>
<term>Urologie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Purpose: Tm:YAG vapoenucleation was introduced as a minimally invasive treatment in patients with benign prostatic obstruction. The efficiency and safety of Tm:YAG vapoenucleation must still be confirmed in large volume prostates to prove the size independence of this promising treatment option. We evaluated the safety and efficiency of Tm:YAG vapoenucleation in patients with a prostate volume of 80 cc or greater and benign prostatic obstruction during a 12-month followup. Materials and Methods: Included in this trial were 90 consecutive patients undergoing 90 W Tm:YAG vapoenucleation. Vapoenucleation was done using the 2 μm continuous wave Tm:YAG laser combined with a mechanical tissue morcellator. We analyzed patient demographic, perioperative and 12-month followup data. Complications were assessed. Results: Mean preoperative prostate volume was 108.6 cc (range 80 to 200), mean International Prostate Symptom Score was 23.5 (range 8 to 35) and mean quality of life score was 4.3 (range 1 to 6). There was an 86% reduction (range 67% to 99%) in prostate volume on transrectal ultrasound by 12 months and an 88% decrease (range 58% to 100%) in prostate specific antigen. International Index of Erectile Function score remained stable. Peak urinary flow rate, International Prostate Symptom Score and quality of life improved significantly (p <0.001), as did post-void residual urine. The overall complication rate was manageable. Two patients required blood transfusion and 10 experienced early postoperative stress incontinence. During followup 7% of patients had symptomatic urinary tract infection and 2 had persistent grade I stress urinary incontinence. The reoperation rate due to urethral stricture was 1.8% during the 12-month followup. Conclusions: Tm:YAG vapoenucleation is a safe, effective and size independent treatment option for benign prostatic obstruction. As shown by reductions in transrectal ultrasound prostate volume and prostate specific antigen, complete removal of the adenoma can be achieved by this procedure.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0022-5347</s0>
</fA01>
<fA02 i1="01"><s0>JOURAA</s0>
</fA02>
<fA03 i2="1"><s0>J. urol.</s0>
</fA03>
<fA05><s2>186</s2>
</fA05>
<fA06><s2>6</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Thulium:YAG Vapoenucleation in Large Volume Prostates</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>BACH (Thorsten)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>NETSCH (Christopher)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>POHLMANN (Laura)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>HERRMANN (Thomas R. W.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>GROSS (Andreas J.)</s1>
</fA11>
<fA14 i1="01"><s1>Departments of Urology, Asklepios Hospital Barmbek</s1>
<s2>Hamburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>MHH Medical School of Hannover</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA20><s1>2323-2327</s1>
</fA20>
<fA21><s1>2011</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>2081</s2>
<s5>354000505638820290</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2012 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>28 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>12-0005789</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>The Journal of urology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Purpose: Tm:YAG vapoenucleation was introduced as a minimally invasive treatment in patients with benign prostatic obstruction. The efficiency and safety of Tm:YAG vapoenucleation must still be confirmed in large volume prostates to prove the size independence of this promising treatment option. We evaluated the safety and efficiency of Tm:YAG vapoenucleation in patients with a prostate volume of 80 cc or greater and benign prostatic obstruction during a 12-month followup. Materials and Methods: Included in this trial were 90 consecutive patients undergoing 90 W Tm:YAG vapoenucleation. Vapoenucleation was done using the 2 μm continuous wave Tm:YAG laser combined with a mechanical tissue morcellator. We analyzed patient demographic, perioperative and 12-month followup data. Complications were assessed. Results: Mean preoperative prostate volume was 108.6 cc (range 80 to 200), mean International Prostate Symptom Score was 23.5 (range 8 to 35) and mean quality of life score was 4.3 (range 1 to 6). There was an 86% reduction (range 67% to 99%) in prostate volume on transrectal ultrasound by 12 months and an 88% decrease (range 58% to 100%) in prostate specific antigen. International Index of Erectile Function score remained stable. Peak urinary flow rate, International Prostate Symptom Score and quality of life improved significantly (p <0.001), as did post-void residual urine. The overall complication rate was manageable. Two patients required blood transfusion and 10 experienced early postoperative stress incontinence. During followup 7% of patients had symptomatic urinary tract infection and 2 had persistent grade I stress urinary incontinence. The reoperation rate due to urethral stricture was 1.8% during the 12-month followup. Conclusions: Tm:YAG vapoenucleation is a safe, effective and size independent treatment option for benign prostatic obstruction. As shown by reductions in transrectal ultrasound prostate volume and prostate specific antigen, complete removal of the adenoma can be achieved by this procedure.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B14D02</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B20B02</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Adénome de la prostate</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Benign prostatic hyperplasia</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Hiperplasia prostática benigna</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Thulium</s0>
<s2>NC</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Thulium</s0>
<s2>NC</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Tulio</s0>
<s2>NC</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Volume</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Volume</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Volumen</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Prostate</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Prostate</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Prostata</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Laser</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Laser</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Láser</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Traitement</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Treatment</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Volatilisation</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Volatilization</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Volatilización</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Néphrologie</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Nephrology</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Nefrología</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Urologie</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Urology</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Urología</s0>
<s5>12</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Appareil urogénital</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Urogenital system</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Aparato urogenital</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Pathologie de l'appareil génital mâle</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Male genital diseases</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Aparato genital macho patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Pathologie de l'appareil urinaire</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Urinary system disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Aparato urinario patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Tumeur bénigne</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Benign neoplasm</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Tumor benigno</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Pathologie de la prostate</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Prostate disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Prostata patología</s0>
<s5>41</s5>
</fC07>
<fN21><s1>002</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Terre/explor/ThuliumV1/Data/Pascal/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000192 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Pascal/Curation/biblio.hfd -nk 000192 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Terre
   |area=    ThuliumV1
   |flux=    Pascal
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:12-0005789
   |texte=   Thulium:YAG Vapoenucleation in Large Volume Prostates
}}

This area was generated with Dilib version V0.6.21.
Data generation: Thu May 12 08:27:09 2016. Site generation: Thu Mar 7 22:33:44 2024

	Serveur d'exploration sur le thulium
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le thulium

Thulium:YAG Vapoenucleation in Large Volume Prostates

Thulium:YAG Vapoenucleation in Large Volume Prostates

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri